Zoledronic acid in the treatment of hypercalcemia of malignancy: Results of the international clinical development program

Seminars in Oncology

Volumn 28, Issue 2 SUPPL. 6, 2001, Pages 17-24

  Major, Pierre P ^a   Coleman, Robert E ^a,b  

^a JURAVINSKI CANCER CENTRE   (Canada)

^b WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; PAMIDRONIC ACID; ZOLEDRONIC ACID;

BONE PAIN; CLINICAL TRIAL; CONJUNCTIVITIS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEVER; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; PRIORITY JOURNAL; RECURRENT DISEASE; RETREATMENT; REVIEW;

EID: 0034980134     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.24156     Document Type: Review

References (30)

1. Cancer-associated hypercalcemia: Morbidity and mortality
2. Clinical manifestations of cancer-related hypercalcemia
3. Biochemical evaluation of patients with cancer-associated hypercalcemia: Evidence for humoral and non-humoral groups
4. Parathyroid hormone related protein: Elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer
5. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-, 60-, and 90-mg dosages
6. Comparison of three intravenous bisphosphonates in cancer-associated hyper-calcemia
7. Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia
8. A randomized, double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia
9. Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in the hypercalcemia of malignancy
10. Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD) as single shot treatment of hypercalcaemia
11. Comparative tolerability of drug therapies for hypercalcaemia of malignancy
12. Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate
13. Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: A randomized comparison between a 3-day treatment and single 24-hour infusions
14. Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer
15. A single-day treatment of tumor-induced hypercalcemia by intravenous aminohydroxypropylidene bisphosphonate
16. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy
17. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia
18. Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: A prospective randomized crossover trial
19. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone
20. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate
21. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: The role of parathyroid hormone-related protein
22. Preclinical pharmacology of CGP 42′446, a new potent, heterocyclic bisphosphonate compound
23. A dose finding study of zoledronate in hypercalcemic cancer patients
24. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy - A pooled analysis of two randomized, controlled clinical trials
25. Disodium pamidronate versus mithramycin in the management of tumour-associated hypercalcemia
26. Effective treatment of malignant hypercalcemia with a single intravenous infusion of clodronate
27. Effect of a single infusion of alendronate in malignant hypercalcaemia: Dose dependency and comparison with clodronate
28. Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemia
29. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia
30. Biochemical markers of bone remodeling: Emerging technology